Motor complications in Parkinson's disease: Ten year follow‐up study
暂无分享,去创建一个
Silvia Vázquez-Fernández del Pozo | Iria Cabo López | Pedro J García Ruiz | Silvia Vázquez Fernández Del Pozo | Vicenta Sánchez Bernardos | V. S. Bernardos | P. J. G. Ruiz | I. C. López
[1] A. Schapira. Future directions in the treatment of Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[2] H. Reichmann,et al. Non-motor dysfunction in Parkinson's disease. , 2007, Parkinsonism & related disorders.
[3] John Seibyl,et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.
[4] Werner Poewe,et al. Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa , 2007, Movement disorders : official journal of the Movement Disorder Society.
[5] M. Steiger. Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease , 2007, European journal of neurology.
[6] M. Hely,et al. Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.
[7] K. Beusterien,et al. Antipsychotic drug use among nursing home residents taking rivastigmine. , 2006, Journal of the American Medical Directors Association.
[8] M. Hely,et al. The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years , 1999, Journal of neurology, neurosurgery, and psychiatry.
[9] Mick Jagger,et al. (I Can't Get No) Satisfaction , 2011 .
[10] A. Lees,et al. Ten-year follow-up of three different initial treatments in de-novo PD: A randomized trial , 2001 .
[11] M. Muenter,et al. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.
[12] D. Brooks,et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.
[13] A. Siderowf,et al. Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial , 2002, Movement disorders : official journal of the Movement Disorder Society.
[14] A. Lang,et al. Levodopa‐related motor complications—Phenomenology , 2008, Movement disorders : official journal of the Movement Disorder Society.
[15] O Rascol. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group , 2000 .
[16] A. Barbeau. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. , 1969, Canadian Medical Association journal.
[17] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.
[18] Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.
[19] Fabrizio Stocchi,et al. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications , 2006, The Lancet Neurology.
[20] John Seibyl,et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.
[21] V. Fung,et al. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone , 2009, Movement disorders : official journal of the Movement Disorder Society.
[22] A. Lees,et al. Ten-year follow-up of three different initial treatments in de-novo PD , 2001, Neurology.
[23] E. Meseguer,et al. Motor Complications in Parkinson Disease:: A Prospective Follow-Up Study , 2004, Clinical neuropharmacology.